Septodont, a leading manufacturer of dental products, and Acteon, a leading manufacturer of dental products and medical devices, finalized the acquisition of Laboratorios Inibsa, a global pharmaceutical group located in Barcelona (Spain) specializing in the development and manufacturing of products for dental practitioners and dental professionals. Septodont acquired a majority and controlling interest, alongside Acteon as partner and reference shareholder.
Inibsa has over 75 years’ experience in supplying products and services to healthcare professionals, with a growing focus on the dental industry. This acquisition offers the company an exceptional opportunity to expand its sales of dental products on a global scale, with an already established presence in over 60 countries.
Through this acquisition, Septodont is enhancing its production capacities and accelerating its growth in key international markets. For Acteon, majority shareholder of the family investment holding company Dentressangle, the investment is aimed at further developing the existing partnership with Inibsa, while strengthening its position as a manufacturer of dental pharmaceuticals.
“This acquisition of control of Inibsa will expand Septodont’s development in dental products and help us further strengthen our geographical footprint”, said Olivier Schiller, CEO of Septodont. “This is an important acquisition for us that will provide compelling value creation and accelerated growth opportunities given the complementary nature of our assets and teams.”
“We are thrilled to invest in Inibsa alongside Septodont. It will give Acteon the opportunity to strengthen its manufacturing position in the area of dental pharmaceutical products in Europe and Asia”, added Markus Boehringer, CEO of Acteon. “Our shareholders were very supportive of this acquisition, which is the perfect complement of our current strategy, focusing on effective innovation, enhancing our customer service and strengthening operational capabilities.”
A cross-border Dentons team advised Septodont on this transaction. Partner Jean-Marc Grosperrin, led the team, assisted by Emmanuelle De Schepper, Of Counsel, Pascal Chadenet and CĂ©cile Bayle, partners, and Alexis Doise, Dora Pucci and Charlotte Berger, associates, from the Corporate and M&A team. Emmanuelle van den Broucke, partner in Competition and Antitrust, also provided regulatory support. A multidisciplinary team from Madrid — led by partner Nieves Briz and assisted by counsel Natalia Ontiveros, partner Javier Moya, managing counsel Juan Alonso Berberena, and associates Angela De la Iglesia, Gabriel Mendez, Antonio Carmona, Ana Losada, and Nora Pallaruelo — handled the Spanish legal aspects of this acquisition. Additionally, Konstantin Kroll, partner, and senior associate Mikhail Panferov advised on specific regulatory aspects of the transaction.
This acquisition underscores Dentons’ commitment to guiding clients through complex strategic transactions, enabling Septodont to solidify its position in the dental market while strengthening its production network and supply chain.
